专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009131245A1 IMINOPYRIDINE DERIVATIVES AND USE THEREOF 审中-公开
标题翻译：亚氨基吡啶衍生物及其用途
公开(公告)号：WO2009131245A1
公开(公告)日：2009-10-29
申请号：PCT/JP2009/058434
申请日：2009-04-22
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , YOSHIDA, Masato , SAKAUCHI, Nobuki , SATO, Ayumu
发明人： YOSHIDA, Masato , SAKAUCHI, Nobuki , SATO, Ayumu
IPC分类号： C07D213/82 , A61K31/44 , A61P13/02
CPC分类号： C07D213/82
摘要： The present invention aims to provide an iminopyridine derivative compound having an α1D adrenergic receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of a lower urinary tract disease and the like.The present invention provides a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.
摘要翻译：本发明的目的在于提供具有a1D肾上腺素能受体拮抗作用的亚氨基吡啶衍生物化合物，其可用作预防或治疗下尿路疾病等。本发明提供下式表示的化合物，其中每个符号如说明书中所定义，或其盐。

2. 发明申请

WO2004017908A3 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF 审中-公开
公开(公告)号：WO2004017908A3
公开(公告)日：2004-03-04
申请号：PCT/US2003/026317
申请日：2003-08-21
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED , YASUMA, Tsuneo , MORI, Akira , KAWASE, Masahiro , KIMURA, Hiroyuki , YOSHIDA, Masato , GYORKOS, Albert, Charles , PRATT, Scott, Alan , CORRETTE, Christopher, Peter
发明人： YASUMA, Tsuneo , MORI, Akira , KAWASE, Masahiro , KIMURA, Hiroyuki , YOSHIDA, Masato , GYORKOS, Albert, Charles , PRATT, Scott, Alan , CORRETTE, Christopher, Peter
IPC分类号： C07D221/04
摘要： There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7- membered ring; ring B is an optionally substituted 5- to 7- membered heterocyclic ring; X 1 is CR 1 , CR 1 R 2 , N or NR 13 ; X 2 is N or NR 3 ; Y is C, CR 4 or N, Z is CR 5 , CR 5 R 6 , N or NR 7 ; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and --- is a single bond or a double bond; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7- membered ring; Q is C, CR 5 or N; R 8 , R 9 ,R 10 , R 11 and R 12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X 1 , R 3 , R 1 , Y and X 3 in formula (II) and (III) as before.

3. 发明申请

WO2015068856A1 PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS 审中-公开
标题翻译：用于治疗自身免疫疾病的吡咯
公开(公告)号：WO2015068856A1
公开(公告)日：2015-05-14
申请号：PCT/JP2014/080005
申请日：2014-11-05
申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED
发明人： YOSHIDA, Masato , TAKAMI, Kazuaki , TOMINARI, Yusuke , SHIOKAWA, Zenyu , SHIBUYA, Akito , SASAKI, Yusuke , GIBSON, Tony , TAKAGI, Terufumi
IPC分类号： C07D401/14 , C07D413/14 , A61K31/4155 , C07D401/04 , C07D403/14 , C07D409/14 , C07D417/14 , C07D487/04 , C07D487/10 , A61P37/00
CPC分类号： C07D413/14 , A61K9/06 , A61K9/2018 , A61K9/2054 , A61K9/4858 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10 , C07D491/107 , C07D495/04
摘要： The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.
摘要翻译：本发明提供了具有IRAK-4抑制作用的杂环化合物，其可用于预防或治疗炎症性疾病，自身免疫性疾病，骨关节炎性退行性疾病，肿瘤性疾病等，以及含有它们的药物。本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。

4. 发明申请

WO2005035426A1 ESCALATOR AND SKIRT END STRUCTURE 审中-公开
标题翻译：自动化和结构结构
公开(公告)号：WO2005035426A1
公开(公告)日：2005-04-21
申请号：PCT/JP2004/015304
申请日：2004-10-08
申请人： TOSHIBA ELEVATOR KABUSHIKI KAISHA , YOSHIDA, Masato
发明人： YOSHIDA, Masato
IPC分类号： B66B29/04
CPC分类号： B66B29/04 , B66B27/00
摘要： There is provided an escalator having a skirt end portion which is improved in the visibility of an indicator, etc. and in the safety of the transport of passengers. The escalator, having a pair of balustrades disposed on both sides of traveling steps, includes: a balustrade end for turning back a handrail belt wound around on each said balustrade; a skirt end portion having a belt entrance port for the handrail belt; and an indicator for indicating the operating conditions of the escalator, wherein the front face of the skirt end portion includes an inclined surface at predetermined angles with a vertical plane and with the direction of passengers' riding from the entrance to the escalator, and the indicator is disposed such that its display face conforms to the inclination of the inclined surface.
摘要翻译：提供了具有裙部端部的自动扶梯，其提高了指示器的可视性等，并且在乘客的运输的安全性方面。自动扶梯具有设置在行进台阶两侧的一对栏杆，包括：用于转回围绕每个所述栏杆的扶手带的栏杆端; 裙部端部具有用于扶手带的带入口; 以及用于指示自动扶梯的操作条件的指示器，其中裙部端部的前表面包括具有垂直平面的预定角度的倾斜表面以及乘客从入口到自动扶梯的乘坐方向，并且指示器被布置成使得其显示面符合倾斜表面的倾斜度。

5. 发明公开

EP3066094A1 PYRAZOLE FOR THE TREATMENT AUTOIMMUNE DISORDERS 有权转让
标题翻译：吡唑用于自身免疫性疾病的治疗
公开(公告)号：EP3066094A1
公开(公告)日：2016-09-14
申请号：EP14805371.3
申请日：2014-11-05
申请人： Takeda Pharmaceutical Company Limited
发明人： YOSHIDA, Masato , TAKAMI, Kazuaki , TOMINARI, Yusuke , SHIOKAWA, Zenyu , SHIBUYA, Akito , SASAKI, Yusuke , GIBSON, Tony , TAKAGI, Terufumi
IPC分类号： C07D401/14 , C07D413/14 , A61K31/4155 , C07D401/04 , C07D403/14 , C07D409/14 , C07D417/14 , C07D487/04 , C07D487/10 , A61P37/00
摘要： The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

6. 发明公开

EP1572113A2 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF 有权转让
标题翻译： CALRIUM-REZEPTOR-MODULIERENDE VERBINDUNG UND IHRE VERWENDUNG
公开(公告)号：EP1572113A2
公开(公告)日：2005-09-14
申请号：EP03793273.8
申请日：2003-08-21
申请人： Takeda Pharmaceutical Company Limited
发明人： YASUMA, Tsuneo , MORI, Akira , KAWASE, Masahiro , KIMURA, Hiroyuki , YOSHIDA, Masato , GYORKOS, Albert, Charles , PRATT, Scott, Alan , CORRETTE, Christopher, Peter
IPC分类号： A61K6/00
CPC分类号： C07D487/04
摘要： There is provided a calcium receptor modulator comprising a compound of the formula (I): wherein ring A is an optionally substituted 5- to 7- membered ring; ring B is an optionally substituted 5- to 7- membered heterocyclic ring; X1 is CR1, CR1R2, N or NR13; X2 is N or NR3; Y is C, CR4 or N, Z is CR5, CR5R6, N or NR7; Ar is an optionally substituted cyclic group; R is H, an optionally substituted hydrocarbon group, etc.; and --- is a single bond or a double bond; R1, R2, R3, R4, R5, R6, R7 and R13 are independently H, an optionally substituted hydrocarbon group; or a salt thereof or a prodrug thereof. Compounds of the formula (II) and (III): wherein ring A is an optionally substituted 5- to 7- membered ring; Q is C, CR5 or N; R8, R9,R10, R11 and R12 are independently, H, an optionally substituted hydrocarbon group, etc., or a salt thereof are also provided. Also specify X1, R3, R1, Y and X3 in formula (II) and (III) as before.
摘要翻译：提供了包含式（I）化合物的钙受体调节剂：其中环A是任选取代的5-至7-元环; 环B是任选取代的5-至7-元杂环; X1是CR1，CR1R2，N或NR13; X2为N或NR3; Y为C，CR4或N，Z为CR5，CR5R6，N或NR7; Ar是任选取代的环状基团; R为H，任选取代的烃基等; ＆lt; img id =“CUSTOM-CHARACTER-00001”he =“3.13mm”wi =“8.47mm”file =“US20090215746A1-20090827-P00001.TIF”img-content =“character”img-format =“tif”/ >是单键或双键; R 1，R 2，R 3，R 4，R 5，R 6，R 7和R 13独立地为H，任选取代的烃基; 或其盐或其前药。式（II）和（III）的化合物：其中环A是任选取代的5-至7-元环; Q为C，CR5或N; R8，R9，R10，R11和R12独立地为H，任意取代的烃基等，或其盐。也如前所述，在式（II）和（III）中指定X1，R3，R1，Y和X3。

7. 发明公开

EP3514150A1 HETEROCYCLIC AMIDE COMPOUND 审中-公开
公开(公告)号：EP3514150A1
公开(公告)日：2019-07-24
申请号：EP17850967.5
申请日：2017-09-14
申请人： Takeda Pharmaceutical Company Limited
发明人： HIRAYAMA, Takaharu , HIRATA,Yasuhiro , TOMINARI, Yusuke , IWAMURA, Naoki , SASAKI, Yusuke , ASANO, Moriteru , TAKAGI, Terufumi , OKANIWA,Masanori , YOSHIDA, Masato , IMAMURA, Shinichi
IPC分类号： C07D401/04 , A61K31/4439 , A61K31/444 , A61K31/506 , A61P35/00 , A61P43/00 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D417/14 , C12N9/99
摘要： Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I):

wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

8. 发明授权

EP1572113B1 CALCIUM RECEPTOR MODULATING COMPOUND AND USE THEREOF 有权转让
标题翻译：钙受体调节化合物及其用途
公开(公告)号：EP1572113B1
公开(公告)日：2017-05-17
申请号：EP03793273.8
申请日：2003-08-21
申请人： Takeda Pharmaceutical Company Limited
发明人： YASUMA, Tsuneo , MORI, Akira , KAWASE, Masahiro , KIMURA, Hiroyuki , YOSHIDA, Masato , GYORKOS, Albert, Charles , PRATT, Scott, Alan , CORRETTE, Christopher, Peter
IPC分类号： C07D487/04 , C07D221/04 , C07D471/04 , A61K31/519 , A61K31/473 , A61K31/551 , A61K31/53 , A61P19/10
CPC分类号： C07D487/04

9. 发明公开

EP2818473A1 HETEROCYCLIC COMPOUND 审中-公开
标题翻译：杂环化合物
公开(公告)号：EP2818473A1
公开(公告)日：2014-12-31
申请号：EP13751296.8
申请日：2013-02-19
申请人： Takeda Pharmaceutical Company Limited
发明人： NAGAMIYA, Hiroyuki , YOSHIDA, Masato , SETO, Masaki , MARUI, Shogo , ODA, Tsuneo , ISHICHI, Yuji , SUZUKI, Hideo , KUSUMOTO, Tomokazu , YOGO, Takatoshi , RHIM, Chul Yun , YOON, Cheolhwan , LEE, Gil Nam , KANG, Hyun Bin , KIM, Kwang Ok , JEON, Hye Sun
IPC分类号： C07D471/04 , A61K31/437 , A61K31/444 , A61K31/496 , A61K31/497 , A61K31/506 , A61P1/04 , A61P17/00 , A61P17/06 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/02 , A61P37/06 , A61P43/00
CPC分类号： C07D471/04 , C07D519/00
摘要： The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action.
The present invention relates to a compound represented by the formula

wherein each symbol is as defined in the specification, or a salt thereof.
摘要翻译：本发明提供了用于预防或治疗自身免疫性疾病（例如牛皮癣，类风湿性关节炎，炎性肠病，舍格伦综合征，白塞病，多发性硬化症，系统性红斑狼疮等）的药剂等，其具有优良的Tyk2 抑制作用。本发明涉及由下式表示的化合物或其盐，其中每个符号如说明书中所定义。

10. 发明公开

EP4389893A1 HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE 审中-实审
公开(公告)号：EP4389893A1
公开(公告)日：2024-06-26
申请号：EP22861282.6
申请日：2022-08-19
申请人： Takeda Pharmaceutical Company Limited
发明人： YOGO, Takatoshi , SUGIYAMA, Hideyuki , MIYATA, Kenichi , TAKADA, Hiroyuki , YOSHIDA, Masato , TOKUNOH, Ryosuke , NAKAGAWA, Yasuo , NIWA, Masato , SASAKI, Shigekazu , OHUCHI, Masaki , SAWAI, Naoki , TAKUWA, Masatoshi , UCHINO, Yujiro , KANEMATSU, Yoko , FUKUDA, Koichiro , YOKOTA, Takanori , NAGATA, Tetsuya , YAMADA, Hiroki
IPC分类号： C12N15/113 , A61K31/7088 , A61K31/712 , A61K31/7125 , A61K31/713 , A61K38/10 , A61K47/64 , A61K48/00 , A61P21/00 , C07K7/08
CPC分类号： A61K31/7088 , A61K31/712 , A61K31/7125 , A61K31/713 , A61K38/10 , A61K47/64 , A61K48/00 , A61P21/00 , C07K7/08 , C12N15/113
摘要： The present invention aims to provide a novel drug delivery system (DDS) technique capable of selectively delivering a drug (compound containing oligonucleotides for producing at least partially functional dystrophin protein) to muscle tissues such as cardiac muscle, skeletal muscle and the like and efficiently introducing the drug into the muscle cells. The present invention relates to a conjugate or a salt thereof including the following: (1) a peptide that binds to a transferrin receptor, and contains the amino acid sequence shown in SEQ ID NO: 1 (Ala-Val-Phe-Val-Trp-Asn-Tyr-Tyr-Ile-Ile-Ser-Cys); or an amino acid sequence resulting from substitution, deletion, addition, and/or insertion of not less than one and not more than 10 amino acid residues in the amino acid sequence shown in SEQ ID NO: 1, and (2) a compound comprising an oligonucleotide for producing an at least partially functional dystrophin protein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式